StockVS

Archimedes Tech SPAC Partners III Co. (ARCI) Aandelenanalyse

Financiële Diensten

Archimedes Tech SPAC Partners III Co.

$9.96

+$0.00 (+0.00%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

Archimedes Tech SPAC Partners III Co. is a specialized entity dedicated to executing business combinations through mechanisms such as mergers, amalgamations, share exchanges, asset acquisitions, share purchases, or reorganizations with one or more businesses. The company operates within the Financial Services sector, specifically classified under the industry of Shell Companies, which implies a corporate structure existing primarily to facilitate a merger with an operating business rather than conducting standalone commercial activities. As of the latest available data, the entity holds a market capitalization of $348.74M, while its annual revenue and employee count are not publicly disclosed as N/A in the provided financial records. The market cap of $348.74M indicates that the valuation is assigned to the SPAC vehicle itself prior to its merger with a target operating company, a common characteristic for shell companies where the asset base consists mainly of the trust account cash rather than operational revenues. This valuation scale reflects the market's pricing of the potential future value of the merger target, distinguishing it from traditional operating companies where market cap correlates directly with current earnings and sales figures.

Financiële gezondheid

The company reports a net income of $-166,850 over the trailing twelve months, while revenue and EBITDA figures are listed as N/A, a status typical for SPACs awaiting their initial business combination. The absence of reported revenue and the presence of a net loss reveal a cost structure where operating expenses, such as legal, accounting, and administrative fees, exceed any nominal revenue generated during the interim period. Free cash flow is not disclosed, indicating that the company's financial flexibility currently relies on the proceeds from its initial public offering and the funds held in its trust account rather than operational cash generation. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, which collectively indicate that the company has not yet generated profitable operations or that revenue is insufficient to cover costs, resulting in zero margin realization. In terms of leverage, both total cash and total debt are listed as N/A, meaning the debt-to-equity ratio is also unavailable, though the financial structure of a shell company typically involves minimal long-term debt until the merger closes. The current ratio stands at 0.11, a figure that suggests the company possesses significantly fewer current assets than current liabilities, a metric that often reflects the specific accounting treatment of SPAC trust accounts which are restricted and not always counted as freely available current assets for liquidity purposes. Return on equity and return on assets are both listed as N/A, which prevents a quantitative assessment of management effectiveness in generating returns on the invested capital during the shell period.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E ratio are both listed as N/A, a standard metric status for non-profitable or pre-merger entities where the denominator for the calculation is zero or undefined, rendering the difference between them inapplicable for assessing an earnings trajectory at this stage. The price-to-book ratio is reported at -1098.89, a negative figure that indicates the market price is trading below the book value of equity, a phenomenon often observed in SPACs where the book value consists almost entirely of restricted trust cash that cannot be used for operations or dividends. The price-to-sales ratio and EV/EBITDA are also N/A, suggesting that traditional multiple-based valuation comparisons with operating companies are not currently possible due to the lack of sales and earnings data. The stock has traded within a tight range defined by a 52-week high of $9.94 and a 52-week low of $9.83, indicating minimal price fluctuation over the last year. Without a specific current price provided in the available facts to calculate the exact percentage deviation, the trading range suggests low volatility typical for SPACs in the pre-business combination phase where the primary risk is the failure to secure a merger rather than market price swings. The beta value is listed as N/A, which implies that the stock's volatility relative to the broader market cannot be statistically modeled using historical data due to the limited trading history or specific constraints of the SPAC structure.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which precludes any analysis of whether earnings are growing faster or slower than revenue at this specific moment in the company's lifecycle. Since the company does not pay dividends, as indicated by the N/A dividend yield and payout ratio, the entity does not distribute income to shareholders, and instead reinvests any available earnings or trust assets into the pursuit of a suitable merger target. The company's overall growth and income profile is characterized by a reliance on the successful execution of a business combination rather than organic revenue expansion or dividend yield strategies. Consequently, the investment thesis rests entirely on the potential value creation from the merger transaction, as the current financial metrics do not support a growth or income strategy typical of mature Financial Services companies.

Vergelijking met sectorgenoten

Archimedes Tech SPAC Partners III Co. (ARCI) is actief in de Lege Vennootschappen-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
Archimedes Tech SPAC Partners III Co. ARCI $351.21M N/A
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

De gemiddelde K/W-verhouding in de Lege Vennootschappen-sector is 82.8x. Archimedes Tech SPAC Partners III Co. wordt verhandeld tegen een K/W van N/A.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over Archimedes Tech SPAC Partners III Co.

Archimedes Tech SPAC Partners III Co. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2025 and is based in Claymont, Delaware.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$351.21M
K/W-verhouding
N/A
52-weken hoog
$10.06
52-weken laag
$9.83
Gem. Volume
38.43K

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
United States